Literature DB >> 16230071

National adherence to evidence-based guidelines for the prescription of nonsteroidal anti-inflammatory drugs.

Neena S Abraham1, Hashem B El-Serag, Michael L Johnson, Christine Hartman, Peter Richardson, Wayne A Ray, Walter Smalley.   

Abstract

BACKGROUND & AIMS: Our objective was to assess adherence to evidence-based guidelines by providers of the Department of Veterans Affairs nationwide.
METHODS: This was a cross-sectional study among veterans prescribed a nonsteroidal anti-inflammatory drug (NSAID) from January 1, 2002, to December 31, 2002. Prescription data were linked to inpatient and outpatient medical records and death files. The population was characterized as high risk based on the following: age 65 years or older, concurrent corticosteroid or anticoagulant use, history of peptic ulcer, and high average daily dose of NSAIDs. Adherence was defined as the prescription of a traditional NSAID with gastroprotection or a coxib in high-risk NSAID users. Univariate and multivariate analyses assessed the potential predictors of adherence.
RESULTS: Three hundred three thousand seven hundred eighty-seven met our definition of high risk. Most (97.3%) were male; 55.6% were white, 9.6% black, and 34.8% of other/unknown race. Age 65 years or older was the largest high-risk subset (87.1%). Overall, only 27.2% of high-risk veterans (n = 82,766) were prescribed an adherent strategy. Among veterans with at least 2 risk factors, adherence was 39.7%; among those with 3 risk factors, adherence was 41.8%. Predictors of adherence included history of upper gastrointestinal events, anticoagulant use, rheumatologic disease, high Deyo comorbidity index score, use of low-dose salicylates, and concurrent corticosteroid use. Predictors of nonadherence included prescriptions > or =90 days and high average daily dose of NSAIDs.
CONCLUSIONS: Adherence to evidence-based guidelines for safe prescription of NSAIDs in the Department of Veterans Affairs is low (27.2%). The likelihood of adherence is further decreased if veterans are prescribed NSAIDs for > or=90 days.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16230071     DOI: 10.1053/j.gastro.2005.08.003

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  38 in total

1.  Association between adherence to evidence-based guidelines for the prescription of non-steroidal anti-inflammatory drugs and the incidence of gastric mucosal lesions in Japanese patients.

Authors:  Hidetaka Tsumura; Tsuyoshi Fujita; Isamu Tamura; Yoshinori Morita; Masaru Yoshida; Takashi Toyonaga; Hidekazu Mukai; Hideto Inokuchi; Hiromu Kutsumi; Takeshi Azuma
Journal:  J Gastroenterol       Date:  2010-05-25       Impact factor: 7.527

2.  Proton pump inhibitors and gastric neoplasia.

Authors:  E J Kuipers
Journal:  Gut       Date:  2006-09       Impact factor: 23.059

3.  Primary prevention of adverse gastroduodenal effects from short-term use of non-steroidal anti-inflammatory drugs by omeprazole 20 mg in healthy subjects: a randomized, double-blind, placebo-controlled study.

Authors:  Jay C Desai; Shefali M Sanyal; Tyralee Goo; Ariel A Benson; Carol A Bodian; Kenneth M Miller; Lawrence B Cohen; James Aisenberg
Journal:  Dig Dis Sci       Date:  2008-01-26       Impact factor: 3.199

4.  Use of nonsteroidal anti-inflammatory drugs and coxibs in the elderly. Are we following the guidelines?

Authors:  Sergio Duran-Barragan; Anthony S Russell
Journal:  Clin Rheumatol       Date:  2008-07-12       Impact factor: 2.980

5.  Association of Proton Pump Inhibitors With Reduced Risk of Warfarin-Related Serious Upper Gastrointestinal Bleeding.

Authors:  Wayne A Ray; Cecilia P Chung; Katherine T Murray; Walter E Smalley; James R Daugherty; William D Dupont; C Michael Stein
Journal:  Gastroenterology       Date:  2016-09-14       Impact factor: 22.682

6.  Trends in Drug Prescription Rates for Dementia: An Observational Population-Based Study in France, 2006-2014.

Authors:  Mathilde François; Jonathan Sicsic; Alexis Elbaz; Nathalie Pelletier Fleury
Journal:  Drugs Aging       Date:  2017-09       Impact factor: 3.923

7.  DUEXIS(®) (ibuprofen 800 mg, famotidine 26.6 mg): a new approach to gastroprotection for patients with chronic pain and inflammation who require treatment with a nonsteroidal anti-inflammatory drug.

Authors:  Alfonso E Bello
Journal:  Ther Adv Musculoskelet Dis       Date:  2012-10       Impact factor: 5.346

8.  Barriers to physician adherence to nonsteroidal anti-inflammatory drug guidelines: a qualitative study.

Authors:  J M Cavazos; A D Naik; A Woofter; N S Abraham
Journal:  Aliment Pharmacol Ther       Date:  2008-09-15       Impact factor: 8.171

9.  Prevention and treatment of NSAID-induced gastroduodenal injury.

Authors:  Angel Lanas
Journal:  Curr Treat Options Gastroenterol       Date:  2006-04

10.  Impact of concomitant low-dose aspirin on the safety and tolerability of naproxen and esomeprazole magnesium delayed-release tablets in patients requiring chronic nonsteroidal anti-inflammatory drug therapy: an analysis from 5 Phase III studies.

Authors:  Dominick J Angiolillo; Catherine Datto; Shane Raines; Neville D Yeomans
Journal:  J Thromb Thrombolysis       Date:  2014-07       Impact factor: 2.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.